Disease | thrombocytopenia |
Symptom | C0023895|liver disease |
Sentences | 22 |
PubMedID- 20565378 | Despite prolonged coagulation times and thrombocytopenia associated with end-stage liver disease, formation of thrombi in the circulation seems to occur more frequently during liver transplant than during any other type of major surgery. |
PubMedID- 23339384 | Correcting thrombocytopenia in patients with liver diseases: a difficult hurdle. |
PubMedID- 21637276 | Small intestinal bacterial overgrowth and helicobacter pylori: can they be cause of thrombocytopenia in patients with chronic liver disease. |
PubMedID- 26573200 | A case report of immune thrombocytopenia with drug induced liver disease. |
PubMedID- 21161560 | Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant staphylococcus aureus-infected patients after digestive surgery. |
PubMedID- 22414142 | Estimates of the prevalence of thrombocytopenia in liver disease vary widely, depending on the population and the platelet threshold used . |
PubMedID- 22257364 | Eltrombopag is not yet licensed for treatment of thrombocytopenia in patients with chronic liver disease because the risk of portal venous thrombosis (pvt) increased substantially when this drug was administered at 75 mg daily for 14 days . |
PubMedID- 24478597 | It is stillcontroversial whether the thrombocytopenia observed in patients with chronic liver diseaseis more associated to splenomegaly or to very high portal blood pressure. |
PubMedID- 24686514 | These agents are currently in development for the treatment of thrombocytopenia in patients with chronic liver disease and liver cirrhosis . |
PubMedID- 23086124 | thrombocytopenia in patients with chronic liver disease: what's in a name. |
PubMedID- 24100055 | Background: thrombocytopenia in patients with end-stage liver disease is a common disorder caused mainly by portal hypertension, low levels of thrombopoetin, and endotoxemia. |
PubMedID- 26501978 | Currently, two global phase iii trials are ongoing evaluating the efficacy and safety of once-daily oral avatrombopag for the treatment of adults with thrombocytopenia associated with liver disease prior to an elective procedure (clinical trial no: nct01972529 and nct01976104). |
PubMedID- 26459859 | Overall the current study gives a better understanding of a novel approach to deal with thrombocytopenia associated with liver diseases with elevated ucb. |
PubMedID- 24932302 | Although eltrombopag is not currently used for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures, the observations of the present study indicated that the short-term administration of eltrombopag may not accelerate the progression of hcc and may be beneficial for hcc treatment in cirrhotic patients with thrombocytopenia. |
PubMedID- 21131941 | thrombocytopenia associated with chronic liver disease: effects of rifaximin on platelet count. |
PubMedID- 24375285 | Co-existing liver disease increases the risk of postoperative thrombocytopenia in patients undergoing hepatic resection: implications for the risk of epidural hematoma associated with the removal of an epidural catheter. |
PubMedID- 20919743 | Given the fact that thrombocytopenia is associated with chronic liver diseases, and the multifunctional nature of platelets we reason that phenotype-specific platelets could be the systemic barometer for hepato-carcinogenesis. |
PubMedID- 22054278 | Romiplostim in chronic liver disease with severe thrombocytopenia undergoing an elective invasive procedure. |
PubMedID- 22674141 | We evaluated the pharmacokinetics, efficacy, and safety of eltrombopag in japanese patients with thrombocytopenia associated with chronic liver disease (cld). |
PubMedID- 24765367 | Further study is needed to determine if splenic artery embolization could have an expanded role in the treatment of patients with severe itp and those who might be treatment failures of first line therapy and other chronic forms of thrombocytopenia particular that associated with advanced liver disease. |
PubMedID- 24696622 | Similarly, chronic liver disease patients with thrombocytopenia who need to undergo an invasive procedure may be potential candidates for short two-week courses of eltrombopag in the periprocedural period to help reduce the risk of bleeding. |
PubMedID- 24714308 | No correlation between the size of the spleen and the amount of platelet specific immunoglobulin was found, and this may partly explain the inconstant relationship between the size of the spleen and the degree of thrombocytopenia in patients with chronic liver disease 9. |
Page: 1